The global market for oligonucleotide synthesis services is witnessing significant growth, driven by increased demand in genomics, molecular diagnostics, gene editing, and nucleic acid therapeutics. According to a recent report added to ResearchAndMarkets.com’s offerings, the market is projected to expand from $2.93 billion in 2025 to approximately $3.21 billion in 2026, marking a compound annual growth rate (CAGR) of 9.7%1. This growth trajectory is anticipated to continue, with the market expected to reach $4.70 billion by 2030, growing at a CAGR of 10%2.
The expansion of the oligonucleotide synthesis services market is largely supported by advancements in gene and cell therapy pipelines, the increasing use of CRISPR technology, and the broader adoption of precision diagnostics. The development of nucleic acid-based therapeutics is also contributing to this growth. Providers with advanced capabilities in manufacturing, purification, and quality control are well-positioned to capitalize on these opportunities as the demand for clinical-grade oligonucleotide production scales up.
Key trends in the market include high-throughput custom production, the creation of modified and labeled DNA and RNA sequences, and the provision of GMP-grade manufacturing and rapid-turnaround services for gene-editing applications. Companies are investing in advanced purification workflows and flexible production platforms to support projects from early discovery through to preclinical development and commercial-scale manufacturing. These capabilities are increasingly important for pharmaceutical, biotechnology, and diagnostic organizations seeking reliable supply chains and consistent product quality.
The shift towards personalized medicine is a major driver of market growth. Advances in genomics and molecular diagnostics are enabling healthcare providers to tailor diagnostic and treatment strategies to individual genetic profiles. Oligonucleotide synthesis services facilitate this shift by providing custom DNA and RNA sequences for patient-specific testing, targeted therapies, and gene-based treatments. This approach is becoming more prevalent as the healthcare industry moves towards more personalized and precise medical solutions.
Regulatory developments underscore the growing importance of personalized treatments. The U.S. Food and Drug Administration approved 16 new personalized treatments for rare diseases in 2023, up from six in 2022. These approvals included seven personalized cancer medicines and three treatments for other conditions. This expanding pipeline is increasing the demand for precise, scalable, and quality-controlled oligonucleotide production3.
Service providers are expanding their DNA and RNA manufacturing capabilities to support therapeutic and diagnostic research. For instance, Oligo Factory Inc. launched a low-scale oligonucleotide synthesis service in May 2025, aimed at early-stage researchers and developers. This service offers custom DNA and RNA production starting at 50 nmol, suitable for applications such as therapeutics, diagnostics, quantitative PCR, next-generation sequencing, and preclinical studies. The service provides turnaround times of four weeks or less and supports production under GMP or ISO 13485 quality frameworks, reducing material waste and lowering early development costs.
Strategic partnerships are enhancing international distribution and customer support. In September 2023, Bioserve Biotechnologies (India) Pvt. Ltd. partnered with BioMavericks Ltd. to expand the marketing and distribution of molecular biology products in the UK. This collaboration aims to improve access to DNA oligonucleotide synthesis services and accelerate adoption across research and diagnostic applications. BioMavericks’ use of artificial intelligence for early-stage biomarker discovery in cancer diagnostics creates potential synergies with custom oligonucleotide production.
Tariffs on specialty reagents, phosphoramidites, and laboratory chemicals are exerting cost pressures on the oligonucleotide synthesis services market. High-purity and chemically modified oligonucleotide production is particularly affected due to its reliance on imported synthesis reagents. Manufacturing and research centers in North America and Europe may face increased procurement costs, potentially raising project budgets and reducing outsourcing volumes among smaller laboratories. However, these challenges are also prompting regional reagent production, supply-chain diversification, and investment in localized oligonucleotide synthesis capacity. This shift could help mitigate some of the cost pressures and ensure more stable supply chains.
Footnotes:
- The market expanded from $2.93 billion in 2025 to an estimated $3.21 billion in 2026. Source.
- The market is projected to reach $4.70 billion by 2030, growing at a CAGR of 10%. Source.
- The U.S. FDA approved 16 new personalized treatments for rare diseases in 2023. Source.
Featured Image: Megapixl @ Jirsak
